STOCK TITAN
  1. Home
  2. Sec-filings
  3. VIR
  4. [8-K] Vir Biotechnology, Inc. Reports Material Event

Vir Biotechnology (VIR) CFO resigns; Brent Sabatini named interim principal financial officer

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Vir Biotechnology, Inc. reports that Executive Vice President and Chief Financial Officer Jason O’Byrne informed the company on July 20, 2026 that he will step down from his role effective August 3, 2026 to pursue another opportunity. The company states that his resignation is not due to any disagreement regarding operations, policies, or practices, and it has begun a search for a permanent successor.

On July 23, 2026, the Board appointed Brent Sabatini, CPA, MBA, currently Senior Vice President and Chief Accounting Officer, as interim principal financial officer, effective August 3, 2026. Sabatini, 52, has served as Vir’s Senior Vice President and Chief Accounting Officer since February 2023 and principal accounting officer since October 2024, and previously held finance leadership roles at Capsida Biotherapeutics and Amgen. He has no reportable related-party transactions, no special arrangements relating to his selection, no family relationships with directors or executives, and will receive no additional compensation for the interim role.

Positive

  • None.

Negative

  • CFO Jason O’Byrne resigns effective August 3, 2026, creating a transition in Vir Biotechnology’s senior finance leadership, though the company notes his departure is not due to any disagreement over operations, policies, or practices.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Effective date of CFO resignation August 3, 2026 Date Jason O’Byrne will step down as Executive Vice President and Chief Financial Officer
Date of CFO notice July 20, 2026 Date Jason O’Byrne informed Vir Biotechnology he would step down
Appointment date of interim principal financial officer July 23, 2026 Date the Board appointed Brent Sabatini as interim principal financial officer
Age of Brent Sabatini 52 Age of Vir Biotechnology’s interim principal financial officer
Service at Amgen Inc. April 2004 to March 2021 Period during which Brent Sabatini worked at Amgen in finance-related roles
Service at Capsida Biotherapeutics March 2021 to February 2023 Period Brent Sabatini worked at Capsida Biotherapeutics, most recently as Head of Finance
principal financial officer financial
"appointed Brent Sabatini, CPA, MBA, Senior Vice President and Chief Accounting Officer of Vir Bio, as interim “principal financial officer”"
The principal financial officer is the senior executive who runs a company's financial operations: preparing and certifying financial reports, managing accounting controls, budgets and cash flow, and advising on financial strategy. Investors care about this role because its competence affects how trustworthy the company’s numbers are, how well it manages risk and capital needs, and the credibility of forecasts—like the chief navigator steering a firm's financial course.
principal accounting officer financial
"served as the “principal accounting officer” of Vir Bio since October 2024"
The Principal Accounting Officer is the person responsible for making sure a company's financial records are accurate and follow the rules. They play a key role in preparing financial reports that show how well the company is doing. This helps investors, managers, and regulators trust the company's financial information.
Regulation S-K regulatory
"transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K"
A set of U.S. Securities and Exchange Commission rules that tell public companies which narrative and qualitative details must be disclosed in filings, such as risk factors, management discussion, executive pay, legal proceedings and business description. Think of it as a standardized checklist or blueprint that ensures investors get the same types of background information from every company so they can compare risks, management quality and strategy before making investment decisions.
Item 404(a) regulatory
"no direct or indirect interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →

FAQ

Why is Vir Biotechnology (VIR) CFO Jason O’Byrne stepping down and when is it effective?
Jason O’Byrne will leave his role as Executive Vice President and Chief Financial Officer on August 3, 2026 to pursue another opportunity. Vir Biotechnology states his resignation is not due to any disagreement on operations, policies, or practices.

Who will serve as interim principal financial officer at Vir Biotechnology (VIR)?
The Board appointed Brent Sabatini, CPA, MBA as interim principal financial officer, effective August 3, 2026. He is currently Senior Vice President and Chief Accounting Officer and has more than two decades of accounting and finance experience at Vir, Capsida Biotherapeutics, and Amgen.

Will Brent Sabatini receive additional compensation for the interim role at Vir Biotechnology (VIR)?
No. Vir Biotechnology states that Brent Sabatini will not receive any adjustment or additional compensation for serving as interim principal financial officer. He will continue under his existing compensation arrangements while performing both his current and interim responsibilities.

What is Brent Sabatini’s background before becoming interim principal financial officer at Vir Biotechnology (VIR)?
Brent Sabatini, 52, has been Senior Vice President and Chief Accounting Officer at Vir since February 2023 and principal accounting officer since October 2024. Previously, he held finance leadership roles at Capsida Biotherapeutics (2021–2023) and Amgen Inc. (2004–2021).
FALSE000170643100017064312026-07-202026-07-200001706431exch:XNAS2026-07-202026-07-20

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
________________________________________
FORM 8-K
________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 20, 2026
________________________________________
Vir Biotechnology, Inc.
(Exact name of Registrant as Specified in Its Charter)
________________________________________
Delaware001-3908381-2730369
(State or Other Jurisdiction
of Incorporation)		(Commission File Number)(IRS Employer
Identification No.)
1800 Owens Street, Suite 900
San Francisco, California
94158
(Address of Principal Executive Offices)(Zip Code)
Registrant’s Telephone Number, Including Area Code: (415) 906-4324
(Former Name or Former Address, if Changed Since Last Report)
________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading
Symbol(s)		Name of each exchange on which registered
Common stock, $0.0001 par valueVIRNasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o


Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On July 20, 2026, Jason O’Byrne, MBA, Executive Vice President and Chief Financial Officer of Vir Biotechnology, Inc. (Vir Bio), informed Vir Bio that he will be stepping down from his role, effective August 3, 2026, to pursue another opportunity. Mr. O’Byrne’s resignation was not because of any disagreement with Vir Bio on any matter relating to Vir Bio’s operations, policies, or practices. Vir Bio has initiated a search for his successor.
Additionally, on July 23, 2026, the Board of Directors of Vir Bio appointed Brent Sabatini, CPA, MBA, Senior Vice President and Chief Accounting Officer of Vir Bio, as interim “principal financial officer” of Vir Bio, effective August 3, 2026. Mr. Sabatini, 52, has served as the Senior Vice President and Chief Accounting Officer of Vir Bio since February 2023 and as the “principal accounting officer” of Vir Bio since October 2024. He has more than two decades of relevant experience; previously, from March 2021 to February 2023, he was at Capsida Biotherapeutics, Inc., most recently as Head of Finance. Prior to that, Mr. Sabatini was at Amgen Inc. from April 2004 to March 2021 where he progressed through various positions of increasing responsibility, including leadership roles in Accounting, Tax and Financial Planning and Analysis. Mr. Sabatini is a Certified Public Accountant and received a B.S. in Accountancy from California State University, Northridge and an MBA from the University of Michigan’s Stephen M. Ross School of Business. There are no arrangements or understandings between Mr. Sabatini and any other persons pursuant to which he was selected as Vir Bio’s interim principal financial officer. There are no family relationships between Mr. Sabatini and any director or executive officer of Vir Bio. Mr. Sabatini has no direct or indirect interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K. Mr. Sabatini will not receive any adjustment to his compensation or any additional compensation in connection with performing the function of interim principal financial officer of Vir Bio.


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
VIR BIOTECHNOLOGY, INC.
Date:July 24, 2026By:/s/ Marianne De Backer
Marianne De Backer, M.Sc., Ph.D., MBA
President and Chief Executive Officer

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

4 documents

Other Documents